Table 3.
Univariate analysis and multivariate analysis of the correlation of the GNPNAT1 expression with overall survival among lung adenocarcinoma patients in GSE72094 cohort.
| Variable | Univariate Cox analysis | Multivariate Cox analysis∗ | ||||||
|---|---|---|---|---|---|---|---|---|
| Coef | HR (95% CI) | z | p value | Coef | HR (95% CI) | z | p value | |
| Age | 0.00696 | 1.01 (0.988-1.03) | 0.702 | 0.483 | ||||
| Gender (male vs. female) | 0.44 | 1.55 (1.07-2.25) | 2.33 | 0.0198 | 0.485 | 1.62 (1.11-2.37) | 2.51 | 0.0122 |
| Stage II (vs. stage I) | 0.758 | 2.13 (1.32-3.44) | 3.11 | 0.00185 | 0.771 | 2.16 (1.34-3.49) | 3.16 | 0.00158 |
| Stage III (vs. stage I) | 1.13 | 3.09 (1.93-4.97) | 4.67 | 3.00E-06 | 1.17 | 3.22 (1.99-5.22) | 4.75 | 2.00E-06 |
| Stage IV (vs. stage I) | 1.21 | 3.35 (1.59-7.06) | 3.18 | 0.00148 | 1.31 | 3.7 (1.75-7.84) | 3.42 | 0.000622 |
| Race (white vs. nonwhite) | -0.0694 | 0.933 (0.38-2.29) | -0.151 | 0.88 | ||||
| Ethnicity (Hispanic and Latino vs. non-Hispanic and Latino) | -0.642 | 0.526 (0.0733-3.78) | -0.638 | 0.524 | ||||
| Tobacco smoking history (ever vs. never) | 0.314 | 1.37 (0.597-3.14) | 0.741 | 0.459 | ||||
| KRAS mutation (yes vs. no) | 0.376 | 1.46 (1-2.12) | 1.97 | 0.0492 | 0.148 | 1.16 (0.786-1.71) | 0.744 | 0.457 |
| EGFR mutation (yes vs. no) | -1.34 | 0.262 (0.0965-0.71) | -2.63 | 0.00849 | -1.07 | 0.344 (0.125-0.951) | -2.06 | 0.0397 |
| STK11 mutation (yes vs. no) | -0.0393 | 0.961 (0.58-1.59) | -0.153 | 0.879 | ||||
| TP53 mutation (yes vs. no) | 0.211 | 1.23 (0.82-1.86) | 1.01 | 0.313 | ||||
| GNPNAT1 | 0.701 | 2.02 (1.36-3) | 3.47 | 0.000521 | 0.565 | 1.76 (1.17-2.65) | 2.71 | 0.00667 |
∗Concordance = 0.699 (se = 0.026), likelihood ratio test = 52.73 on 7 df, p = 4e − 09, Wald test = 50.37 on 7 df, p = 1e − 08, score (logrank) test = 54.68 on 7 df, p = 2e − 09.